Literature DB >> 26594835

Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer.

Baris Turkbey1, Anna M Brown2, Sandeep Sankineni1, Bradford J Wood3, Peter A Pinto4, Peter L Choyke1.   

Abstract

Imaging has traditionally played a minor role in the diagnosis and staging of prostate cancer. However, recent controversies generated by the use of prostate-specific antigen (PSA) screening followed by random biopsy have encouraged the development of new imaging methods for prostate cancer. Multiparametric magnetic resonance imaging (mpMRI) has emerged as the imaging method best able to detect clinically significant prostate cancers and to guide biopsies. Here, the authors explain what mpMRI is and how it is used clinically, especially with regard to high-risk populations, and we discuss the impact of mpMRI on treatment decisions for men with prostate cancer. CA Cancer J Clin 2016;66:326-336.
© 2015 American Cancer Society. © 2015 American Cancer Society.

Entities:  

Keywords:  active surveillance; high risk; multiparametric magnetic resonance imaging (MRI); prostate cancer

Mesh:

Year:  2015        PMID: 26594835      PMCID: PMC7511979          DOI: 10.3322/caac.21333

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  93 in total

1.  Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging.

Authors:  Nicolas Barry Delongchamps; Mathieu Rouanne; Thierry Flam; Frédéric Beuvon; Mathieu Liberatore; Marc Zerbib; François Cornud
Journal:  BJU Int       Date:  2010-11-02       Impact factor: 5.588

2.  Complications, Recovery, and Early Functional Outcomes and Oncologic Control Following In-bore Focal Laser Ablation of Prostate Cancer.

Authors:  Herbert Lepor; Elton Llukani; Daniel Sperling; Jurgen J Fütterer
Journal:  Eur Urol       Date:  2015-06-05       Impact factor: 20.096

Review 3.  Hereditary prostate cancer: epidemiologic and clinical features.

Authors:  B S Carter; G S Bova; T H Beaty; G D Steinberg; B Childs; W B Isaacs; P C Walsh
Journal:  J Urol       Date:  1993-09       Impact factor: 7.450

4.  Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?

Authors:  Baris Turkbey; Vijay P Shah; Yuxi Pang; Marcelino Bernardo; Sheng Xu; Jochen Kruecker; Julia Locklin; Angelo A Baccala; Ardeshir R Rastinehad; Maria J Merino; Joanna H Shih; Bradford J Wood; Peter A Pinto; Peter L Choyke
Journal:  Radiology       Date:  2010-12-21       Impact factor: 11.105

5.  Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up.

Authors:  Soroush Rais-Bahrami; Barış Türkbey; Ardeshir R Rastinehad; Annerleim Walton-Diaz; Anthony N Hoang; M Minhaj Siddiqui; Lambros Stamatakis; Hong Truong; Jeffrey W Nix; Srinivas Vourganti; Kinzya B Grant; Maria J Merino; Peter L Choyke; Peter A Pinto
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

6.  African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.

Authors:  Kosj Yamoah; Curtiland Deville; Neha Vapiwala; Elaine Spangler; Charnita M Zeigler-Johnson; Bruce Malkowicz; David I Lee; Michael Kattan; Adam P Dicker; Timothy R Rebbeck
Journal:  Urol Oncol       Date:  2014-10-07       Impact factor: 3.498

7.  Anxiety in the management of localised prostate cancer by active surveillance.

Authors:  Jake Anderson; Susan Burney; Joanne E Brooker; Lina A Ricciardelli; Jane M Fletcher; Prassannah Satasivam; Mark Frydenberg
Journal:  BJU Int       Date:  2014-07-28       Impact factor: 5.588

8.  Implications and considerations of thermal effects when applying irreversible electroporation tissue ablation therapy.

Authors:  Rafael V Davalos; Suyashree Bhonsle; Robert E Neal
Journal:  Prostate       Date:  2015-03-23       Impact factor: 4.104

9.  Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study.

Authors:  Hashim Uddin Ahmed; Paul Cathcart; Neil McCartan; Alex Kirkham; Clare Allen; Alex Freeman; Mark Emberton
Journal:  Cancer       Date:  2012-01-03       Impact factor: 6.860

10.  Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk.

Authors:  Nandita M deSouza; Veronica A Morgan; Elizabeth Bancroft; S Aslam Sohaib; Sharon L Giles; Zsofia Kote-Jarai; Elena Castro; Steven Hazell; Maysam Jafar; Rosalind Eeles
Journal:  Eur J Radiol Open       Date:  2014
View more
  41 in total

1.  Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy.

Authors:  Luca F Valle; Matthew D Greer; Joanna H Shih; Tristan Barrett; Yan Mee Law; Andrew B Rosenkrantz; Haytham Shebel; Akhil Muthigi; Daniel Su; Maria J Merino; Bradford J Wood; Peter A Pinto; Andra V Krauze; Aradhana Kaushal; Peter L Choyke; Barış Türkbey; Deborah E Citrin
Journal:  Diagn Interv Radiol       Date:  2018 Jan-Feb       Impact factor: 2.630

2.  Evaluation of fitting models for prostate tissue characterization using extended-range b-factor diffusion-weighted imaging.

Authors:  Fredrik Langkilde; Thiele Kobus; Andriy Fedorov; Ruth Dunne; Clare Tempany; Robert V Mulkern; Stephan E Maier
Journal:  Magn Reson Med       Date:  2017-07-17       Impact factor: 4.668

3.  Population net benefit of prostate MRI with high spatiotemporal resolution contrast-enhanced imaging: A decision curve analysis.

Authors:  Vinay Prabhu; Andrew B Rosenkrantz; Ricardo Otazo; Daniel K Sodickson; Stella K Kang
Journal:  J Magn Reson Imaging       Date:  2019-01-10       Impact factor: 4.813

4.  Utility of quantitative apparent diffusion coefficient measurements and normalized apparent diffusion coefficient ratios in the diagnosis of clinically significant peripheral zone prostate cancer.

Authors:  Tan B Nguyen; Alexander Ushinsky; Albert Yang; Michael Nguyentat; Sara Fardin; Edward Uchio; Chandana Lall; Thomas Lee; Roozbeh Houshyar
Journal:  Br J Radiol       Date:  2018-06-21       Impact factor: 3.039

Review 5.  MicroRNAs in prostate cancer: From function to biomarker discovery.

Authors:  Ahmed A Moustafa; Hogyoung Kim; Rasha S Albeltagy; Ola H El-Habit; Asim B Abdel-Mageed
Journal:  Exp Biol Med (Maywood)       Date:  2018-06

Review 6.  Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Jonathan I Epstein; Baris Turkbey; Peter L Choyke; Edward M Schaeffer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

7.  Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis.

Authors:  Hebert Alberto Vargas; Rachel Schor-Bardach; Niamh Long; Anna N Kirzner; Jane D Cunningham; Debra A Goldman; Chaya S Moskowitz; Ramon E Sosa; Evis Sala; David M Panicek; Hedvig Hricak
Journal:  Abdom Radiol (NY)       Date:  2017-01

8.  Accelerated Segmented Diffusion-Weighted Prostate Imaging for Higher Resolution, Higher Geometric Fidelity, and Multi-b Perfusion Estimation.

Authors:  Pelin Aksit Ciris; Jr-Yuan George Chiou; Daniel I Glazer; Tzu-Cheng Chao; Clare M Tempany-Afdhal; Bruno Madore; Stephan E Maier
Journal:  Invest Radiol       Date:  2019-04       Impact factor: 6.016

9.  Developing an effective strategy to improve the detection of significant prostate cancer by combining the 4Kscore and multiparametric MRI.

Authors:  Karim Marzouk; Behfar Ehdaie; Emily Vertosick; Stephen Zappala; Andrew Vickers
Journal:  Urol Oncol       Date:  2019-08-02       Impact factor: 3.498

10.  A urologist's perspective on prostate cancer imaging: past, present, and future.

Authors:  Arvin K George; Baris Turkbey; Subin G Valayil; Akhil Muthigi; Francesca Mertan; Michael Kongnyuy; Peter A Pinto
Journal:  Abdom Radiol (NY)       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.